Quantcast

Latest neutropenia Stories

2009-05-27 08:00:00

Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population THOUSAND OAKS, Calif., May 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as...

838c9e165de184dc2088e417a30f467b1
2009-01-16 13:30:00

Researchers have reported findings that suggest a treatment commonly used to help premature babies fight infection is ineffective.Researchers studied 280 babies born at 31 weeks or under to form their surprising conclusion reported in The Lancet.Doctors have used granulocyte-macrophage colony stimulating factor (GM-CSF) in order to help prematurely born infants naturally boost their immune systems by increasing white blood cell growth to prevent blood poisoning. GM-CSF is effective in...

2009-01-02 15:13:10

A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3). The findings, which are published in the Jan. 1, 2009 issue of The New England Journal of Medicine, were made by an international team of scientists, composed of 14 researchers from the...

2008-12-14 11:19:00

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL(R) (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone. Results from this randomized, parallel-group, open-label, multi-center...

2008-09-08 09:00:08

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium held on September 5-7, 2008 in Washington, DC. A poster entitled, "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated...

2008-08-21 09:00:22

Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS). This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. VIDAZA is also the...

2008-07-28 12:01:07

Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics. The International Union of Basic and Clinical Pharmacology is hosting this Annual Scientific Meeting in Quebec City, Canada from July 27-August 1, 2008. The abstract is entitled "GlycoPEGylated G-CSF XM22...

2008-07-10 09:01:29

RICHMOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- Insmed Inc. , a developer of follow-on biologics and biopharmaceuticals for unmet medical needs, today announced that it has demonstrated the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), compared to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of approximately $1 billion. Human bioequivalence studies utilize...

2007-08-16 06:16:41

By Stewart, Susan Context.-Pulmonary infections are common and often life- threatening in solid organ and stem cell transplant recipients. Understanding their pathology is critical to making improvements in care and survival as well as in surgical techniques, immunosuppression management, prophylaxis, and treatment. Pulmonary infections are particularly common and serious in the susceptible population of lung transplant recipients. Objective.-To summarize recent updates in the field for...

2007-07-20 06:03:59

By Auer, Rebecca Infection is the most common cause of neutrophilia, says Dr Rebecca Auer Neutrophilia is an increase in circulating neutrophils above that expected in a healthy individual of the same age, sex, race and physiological status. TMs represents an increase in the neutrophil count above 7.5 ? 1e'/1 and is one of the most frequently observed changes in the FBC. It is usually due either to a redistribution of white cells or an increase hi bone marrow output. Neutrophilia can...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related